Tuberculosis (TB), a deadly infectious disease, continues to claim countless lives worldwide, with millions of new cases reported annually. The primary treatment for TB involves a combination of first-line anti-tuberculosis drugs (ATDs), including isoniazid, rifampicin, pyrazinamide, and ethambutol. While these medications are crucial for curing TB and preventing its spread, they can also cause a range of adverse reactions, impacting patient tolerance and adherence to treatment.
The adverse reactions to first-line ATDs can vary from mild and temporary symptoms to severe and potentially life-threatening conditions. Hepatotoxicity, a common adverse reaction, affects the liver and can range from mild enzyme elevations to severe hepatitis or liver failure. Neuropathy, another significant reaction, affects the peripheral nerves, causing symptoms like numbness, tingling, and pain. These toxicities not only compromise treatment adherence but also pose challenges in managing multidrug-resistant TB, where interruptions can lead to resistance and poor outcomes.
This review focuses on the common adverse reactions associated with first-line ATDs, specifically hepatotoxicity, peripheral neuropathy, central nervous system (CNS) toxicity, and myelosuppression. By understanding these reactions and implementing evidence-based management strategies, healthcare professionals can guide the treatment of TB patients more effectively.
Effective management of adverse reactions is crucial for optimizing patient care and improving treatment outcomes. By identifying risk factors, implementing appropriate monitoring, and employing effective management techniques, healthcare providers can enhance patient adherence and reduce treatment interruptions.
Hepatotoxicity, one of the most common adverse reactions, is primarily associated with isoniazid, rifampicin, and pyrazinamide. The liver, being the primary organ for metabolizing these drugs, is vulnerable to drug-induced injury. Clinical manifestations can vary, with some patients experiencing no symptoms, while others may have nausea, vomiting, abdominal pain, or jaundice. Risk factors include age, underlying liver disease, and genetic factors. Management involves temporary discontinuation of hepatotoxic drugs and the use of antioxidants like N-acetylcysteine.
Peripheral neuropathy, another significant reaction, is associated with isoniazid and ethambutol. This condition damages the peripheral nerves, leading to neurological symptoms that impact quality of life and treatment adherence. Isoniazid-induced neuropathy is dose-dependent, with higher cumulative doses increasing the risk. Management strategies include vitamin B6 supplementation and dose adjustments.
CNS toxicity, primarily associated with isoniazid, can range from mild symptoms like headache to severe neurological complications. The risk is dose-related, and certain patient populations are at higher risk. Management involves prompt recognition, dose reduction, and the use of anticonvulsants for severe cases.
Myelosuppression, characterized by decreased blood cell production, is associated with rifampicin and pyrazinamide. This reaction can lead to neutropenia, thrombocytopenia, and anemia. Management involves close monitoring of blood counts, dose adjustments, and the use of growth factors for severe cases.
To effectively manage these adverse reactions, a multifaceted approach is required. This includes systematic monitoring, dose adjustments, targeted supportive therapies, and patient education. Risk stratification and interdisciplinary coordination are also crucial for personalized management. By implementing these strategies, healthcare professionals can enhance treatment tolerability, improve outcomes, and contribute to global TB control efforts.
